Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri
NCT02137109 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 400
Last updated 2015-10-20
Summary
The primary objective of the study is to evaluate the safety of natalizumab use in the pediatric multiple sclerosis (MS) population.
Conditions
Interventions
- DRUG
-
natalizumab
Administered as specified in the treatment arm.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Medical Director · Biogen
Eligibility
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-03-31
- Primary Completion
- 2015-10-31
- Completion
- 2015-10-31
More Related Trials
-
Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
NCT00027300 ·Status: COMPLETED ·Phase: PHASE3
-
Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT01440101 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis
NCT01455220 ·Status: COMPLETED ·Phase: NA
-
Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
NCT00559702 ·Status: COMPLETED ·Phase: PHASE1
-
Natalizumab Subcutaneous Immunogenicity and Safety Study
NCT02142192 ·Status: TERMINATED ·Phase: PHASE2
-
Natalizumab Re-Initiation of Dosing
NCT00306592 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study
NCT00937677 ·Status: COMPLETED
-
Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis
NCT00097760 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis
NCT02201108 ·Status: COMPLETED ·Phase: PHASE3
-
Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
NCT01416155 ·Status: COMPLETED ·Phase: PHASE2
-
Open-Label Natalizumab Safety Extension Study
NCT00276172 ·Status: COMPLETED ·Phase: PHASE3
-
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)
NCT01405820 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT05532163 ·Status: TERMINATED ·Phase: PHASE4
-
Validation of a Laboratory Test Measuring Natalizumab (Tysabri®) Serum Levels in MS
NCT02965170 ·Status: COMPLETED
-
The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis
NCT00536120 ·Status: COMPLETED ·Phase: PHASE4
-
Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies
NCT02241785 ·Status: TERMINATED ·Phase: PHASE4
-
Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT02428218 ·Status: WITHDRAWN ·Phase: PHASE3
-
Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis
NCT01396343 ·Status: COMPLETED
-
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants
NCT01485003 ·Status: COMPLETED
-
Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT02283853 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis
NCT05265728 ·Status: TERMINATED ·Phase: PHASE3
-
A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients
NCT00871780 ·Status: COMPLETED ·Phase: PHASE4
-
Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis
NCT01199640 ·Status: COMPLETED ·Phase: PHASE2
-
Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
NCT02555215 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
NCT06735248 ·Status: RECRUITING ·Phase: PHASE2